Core Viewpoint - A class action lawsuit has been filed against C3.ai, alleging that the company and its executives misled investors regarding its financial health and growth prospects, particularly in relation to CEO Thomas M. Siebel's health issues [1][2][3]. Summary by Relevant Sections Lawsuit Details - The lawsuit, titled Liggett v. C3.ai, Inc., claims that C3.ai provided overly optimistic revenue projections while downplaying risks associated with CEO Siebel's health [2]. - The class period for the lawsuit is from February 26, 2025, to August 8, 2025, with a lead plaintiff deadline set for October 21, 2025 [2][4]. Financial Impact - Following C3.ai's financial announcement on August 8, 2025, which revealed preliminary first-quarter results that did not meet expectations and a lowered revenue guidance for the fiscal year, the company's stock price dropped by over 25% [3]. Investigation Focus - The investigation is centered on whether C3.ai's public statements were misleading, particularly regarding the impact of CEO Siebel's health on the company's ability to achieve financial targets [5].

Core Insights - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving F5, Inc., focusing on whether F5 and its executives made false or misleading statements or failed to disclose material information to investors [1][2] Company Overview - F5, Inc. provides multi-cloud application security and delivery solutions [2] Recent Developments - On October 15, 2025, F5 disclosed that a highly sophisticated nation-state threat actor gained unauthorized access to certain F5 systems, maintaining long-term access to systems including the BIG-IP product development environment [3] - The investigation revealed that certain files were exfiltrated, including portions of the BIG-IP source code and information about undisclosed vulnerabilities [3] - Following this revelation, the price of F5 shares experienced a decline [3]

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly making false and misleading statements regarding its drug candidate, sonelokimab (SLK), leading to significant investor losses following disappointing clinical trial results [3][4]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company based in Zug, Switzerland [2]. Legal Action Details - The lawsuit is on behalf of investors who purchased MoonLake shares from March 10, 2024, to September 29, 2025, with a deadline for potential lead plaintiff appointment set for December 15, 2025 [1][2]. - The complaint claims that MoonLake and its executives misrepresented SLK's advantages over traditional monoclonal antibodies, specifically FDA-approved BIMZELX [3]. Clinical Trial Results - On September 28, 2025, MoonLake announced Phase 3 clinical trial results for SLK, which reportedly did not demonstrate efficacy comparable to BIMZELX, leading analysts to label the results as "disastrous" [4]. - Following the announcement, MoonLake's stock plummeted nearly 90%, equating to a loss of $55.75 per share in a single trading session [4].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of MoonLake Immunotherapeutics common stock during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and statements [1][5]. Group 1: Class Action Details - The class action lawsuit is for purchasers of MoonLake common stock between March 10, 2024, and September 29, 2025, inclusive [1]. - Investors who purchased stock during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the law firm directly [3][6]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [4]. Group 3: Allegations Against MoonLake - The complaint alleges that MoonLake made false or misleading statements regarding the efficacy of its product SLK compared to traditional monoclonal antibodies, specifically concerning molecular targets and clinical benefits [5]. - The lawsuit claims that when the true details were revealed, investors suffered damages due to the misleading information provided by the company [5].

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics for alleged violations of federal securities laws, claiming that the company made false statements regarding the efficacy of its drug candidate, sonelokimab [1][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased MoonLake securities between March 10, 2024, and September 29, 2025 [2]. - Allegations include that MoonLake misrepresented the efficacy of sonelokimab, claiming it was superior to other monoclonal antibodies without evidence [3]. - The Phase 3 trial results of sonelokimab were described as "disastrous," leading to a nearly 90% loss in the company's stock value [3]. Group 2: Next Steps - Investors who suffered losses in MoonLake have until December 15, 2025, to request to be appointed as lead plaintiff in the class action [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if successful in the lawsuit [5]. - Bronstein, Gewirtz & Grossman, LLC has a history of recovering hundreds of millions of dollars for investors in securities fraud cases [6].

Core Viewpoint - MoonLake Immunotherapeutics, Inc. is facing a class action lawsuit for investors who purchased securities during the specified class period, indicating potential corporate wrongdoing [1][3]. Company Overview - MoonLake is a clinical stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases [3]. - The company's primary drug candidate is sonelokimab (SLK), aimed at treating hidradenitis suppurativa (HS) [3]. Drug Development - SLK's commercial prospects hinge on its ability to demonstrate efficacy in HS that is comparable or superior to Union Chimique Belge's BIMZELX, an FDA-approved monoclonal antibody for the same indication [3].

Core Viewpoint - A shareholder class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging that the company made materially false and misleading statements regarding its product SLK and its comparison to monoclonal antibodies [1] Summary by Relevant Sections Allegations - The lawsuit claims that the defendants failed to disclose critical information about the differences between Nanobodies and monoclonal antibodies, specifically that: - SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [1] - SLK's unique Nanobody structure does not provide a clinical benefit over BIMZELX's traditional monoclonal structure [1] - The supposed increased tissue penetration of SLK does not lead to improved clinical efficacy [1] - Defendants lacked a reasonable basis for their positive claims regarding SLK's superiority to monoclonal antibodies [1] Legal Information - Shareholders who purchased MoonLake shares between March 10, 2024, and September 29, 2025, and suffered significant losses are encouraged to discuss their legal rights [2] - The deadline to request appointment as lead plaintiff in the case is December 15, 2025 [3]

Core Viewpoint - The MoonLake class action lawsuit alleges that MoonLake Immunotherapeutics and its executives violated the Securities Exchange Act of 1934, impacting investors who purchased its common stock [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases, with its primary drug candidate being sonelokimab (SLK) [3]. Allegations - The lawsuit claims that MoonLake made false or misleading statements regarding SLK's efficacy compared to Union Chimique Belge's BIMZELX, which is an FDA-approved monoclonal antibody for the same condition [4]. - Specific allegations include that SLK and BIMZELX target the same inflammatory cytokines (IL-17A and IL-17F), and that SLK's unique Nanobody structure does not provide superior clinical benefits or efficacy [4]. Stock Performance Impact - Following the announcement of disappointing results from the Phase 3 VELA program on September 28, 2025, which indicated SLK did not demonstrate competitive efficacy against BIMZELX, MoonLake's stock price plummeted nearly 90% [5]. Legal Process - Investors who suffered losses during the class period can seek to become lead plaintiffs in the lawsuit, with a deadline for motions set for December 15, 2025 [2][6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP, the law firm representing the plaintiffs, is recognized as a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7].

Core Points - A class action lawsuit has been filed against MoonLake Immunotherapeutics for alleged violations of the Securities Exchange Act of 1934 [1][2] - The lawsuit claims that MoonLake made false and misleading statements regarding its drug sonelokimab, asserting it was superior to competitors without evidence [2] - The Phase 3 trial results released by the company were deemed "disastrous" by analysts, indicating that public statements were materially misleading [2] Class Action Details - The class period for the lawsuit is from March 10, 2024, to September 29, 2025 [2] - Shareholders who purchased shares during this period are encouraged to contact the law firm for potential lead plaintiff appointments [2][3] - The deadline for filing claims is December 15, 2025 [2] Law Firm Information - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns [4] - The firm represents large hedge funds and alternative asset managers, emphasizing the value of litigation claims [4]

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging that the company misled investors regarding the efficacy of its drug candidate SLK, particularly in comparison to the FDA-approved drug BIMZELX [1][2]. Allegations - The lawsuit claims that during the class period, MoonLake failed to disclose critical information about the differences between its Nanobody drug SLK and traditional monoclonal antibodies, including: - Both SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [2]. - SLK's Nanobody structure does not provide a clinical benefit over BIMZELX's monoclonal structure [2]. - The supposed increased tissue penetration of SLK does not translate to improved clinical efficacy [2]. - Consequently, the positive statements made by the company regarding SLK's superiority lacked a reasonable basis [2]. Stock Price Impact - Following the announcement of the Phase 3 VELA program results on September 28, 2025, which indicated that SLK did not demonstrate competitive efficacy against BIMZELX, MoonLake's stock price plummeted by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [3]. Next Steps for Investors - Shareholders interested in participating in the class action must submit their papers to the court by December 15, 2025, to serve as lead plaintiff, representing other class members in the litigation [4]. - Investors can remain absent class members and still be eligible for recovery without taking any action [4]. Company Background - Robbins LLP, the firm leading the class action, has been focused on shareholder rights litigation since 2002, aiming to help shareholders recover losses and improve corporate governance [5].